Medico Remedies growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue+36.8%+13.7%
EBITDA+13.5%+21.0%
Net Income+30.0%+21.9%
EPS (adj.)+30.0%+21.9%
Total Assets+28.3%+20.6%
Total Equity+21.2%+19.8%
Free Cash Flow+20.1%−10.4%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

MEDICO₹18.98

Medico Remedies Limited

· Pharma & Health
₹ CrorePeersMEDICAMEQHALEOSLABSAAREYDRUGSNECLIFEALBERTDAVDVALIANTLABNATCAPSUQZIMLABMcap ₹158 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue+36.8+13.7
EBITDA+13.5+21.0
Net Income+30.0+21.9
EPS (adj.)+30.0+21.9
Total Assets+28.3+20.6
Total Equity+21.2+19.8
Free Cash Flow+20.1-10.4
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.